Diagnosis and Treatment of Hepatitis C

Choo Q.L. , Kuo G. , Weiner A.J. . Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science 1989; 244: 359–61

Global surveillance and control of hepatitis C. Report of a WHO Consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Virol Hep 1999; 6: 635–47

Armstrong G.L. , Alter M.J. , McQuillan G.M. . The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777–89

Zuckerman A. The elusive hepatitis C virus. BMJ 1989; 299: 871–3

Di Bisceglie A. , Goodman Z. , Ishak K. . Long-term clinical and histological follow up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969–74

El-Ahmady O. , Halim A. , Mansour O. . Incidence of hepatitis C virus in Egyptians. J Hepatol 1994; 21: 687

Bresters D. , Mauser-Bunschoten E.P. , Reesink H.W. . Sexual transmission of hepatitis C virus. Lancet 1993; 342: 210–11

Giovannini M. , Tagger A. , Ribero M.L. . Maternal—infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990; 335: 1166

Poynard T. , Bedossa P. , Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32

Lunel F. Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 1994; 107: 1550–5

Marcellin P. , Descamps V. , Martinot-Peignoux M. . Cryoglobulinaemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993; 104: 272–7

Bruix J. , Calvet X. , Costa J. . Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 334: 1004–6

Courouce A-M , Bouchardeau F. , Girault A. . Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994; 343: 853–4

Davis G. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145–51

National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002;36: S128-34

National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26(suppl. 1): 2S–10S

McHutchison J.G. , Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19: 57–65

National Institutes of Health Consensus Development Conference National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002; 36: S3–20

Manns M.P. , McHutchison J.G. , Gordon S.C. . Peginterferon a2b plus ribavirin compared with interferon a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65

Fried M.W. , Shiffman M.L. , Reddy R. , Smith C. . Peginterferon a2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82

Hadziyannis S.J. , Sette H Jnr , Morgan T.R. . Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346–55

Alberti A. , Benvegnu L. Management of hepatitis C. J Hepatol 2003; 38: S104–18

Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S79–84